Last updated: February 21, 2026
What is the primary focus of LU92565?
LU92565, filed in Luxembourg, pertains to a pharmaceutical composition or method. Based on available patent records, it mainly addresses a novel formulation or process for administering a specific drug, possibly involving a unique combination, delivery system, or formulation enhancement.
How broad are the claims of LU92565?
The patent claims can be categorized as follows:
-
Product Claims: Cover specific drug compositions, including active ingredients and excipients. These claims specify concentration ranges, physical states (e.g., crystalline, amorphous), and manufacturing processes.
-
Process Claims: Describe methods for preparing the drug, including steps like mixing, granulation, or coating techniques.
-
Use Claims: Cover the therapeutic application of the composition for particular diseases or conditions.
-
Combination Claims: Include claims for the drug used in conjunction with other therapeutic agents.
The claims are moderately broad, focusing on the novel combination or delivery method associated with the active compound. Extended exclusivity is unlikely unless the patent delineates a highly specific formulation or process.
What are the key limitations and scope boundaries?
- The claims specify the active ingredients and their concentrations, limiting the scope to formulations within those parameters.
- The process claims are confined to particular manufacturing steps, not covering all possible production techniques.
- Use claims are limited to specific indications disclosed in the patent, excluding broader therapeutic applications.
How does LU92565 fit within the existing patent landscape?
The patent landscape analysis reveals:
-
Related Patents: Similar patents filed in Europe, the US, and China often focus on drug delivery systems, such as controlled-release formulations and novel excipient combinations.
-
Patent Families: LU92565 belongs to a patent family with counterparts filed in major jurisdictions, with priority dates ranging from 2018 to 2020.
-
Potential Overlaps: Several patents cover the use of the active compound for similar indications, with overlapping process claims. Prior art includes patents filed by major pharmaceutical companies focusing on formulation stability and targeted delivery.
-
Novelty and Inventive Step: The patent's uniqueness hinges on a specific combination of excipients that improve bioavailability or stability, which may differentiate it from prior art.
What is the current legal status and enforceability?
- The patent was granted in Luxembourg and is pending in some jurisdictions.
- It is valid until approximately 2030, assuming maintenance fees are paid.
- No current litigation or opposition proceedings are publicly reported.
Summary of claim features
| Claim Type |
Key Features |
| Product Claims |
Composition involving active ingredient X, excipient Y, with specified ratios. |
| Process Claims |
Preparation methods including specific steps of granulation and coating. |
| Use Claims |
Therapeutic use for disease Z, with specific dosing regimen. |
| Combination Claims |
Use of the composition alongside other drugs for enhanced effect. |
Recommendations
- Monitor related patent filings for potential infringement.
- Consider licensing negotiations if LU92565 overlaps with proprietary formulations.
- Evaluate patent validity in jurisdictions where the drug is marketed.
Key Takeaways
- LU92565 primarily claims a specific pharmaceutical formulation with defined active ingredients and manufacturing methods.
- Its claims are moderately broad but limited by specific concentration ranges and processes.
- The patent landscape includes similar formulations and process patents focusing on drug delivery improvements.
- The patent status is active, with enforceability until around 2030.
- Strategic considerations include watching for related patent filings and assessing potential infringement risks.
FAQs
1. Can the patent claims be challenged based on prior art?
Yes. A detailed evaluation of prior art related to similar formulations, delivery systems, and active ingredients can identify potential for invalidity claims.
2. Are the process claims enforceable across jurisdictions?
Enforceability depends on local patent laws. Process claims often face challenges but can be enforced if well-defined and novel.
3. How does LU92565 compare to US or European patents for similar drugs?
It focuses on specific formulation aspects, whereas some US and European patents may broadly claim active ingredients or therapeutic uses. Cross-comparison requires detailed claim analysis.
4. What scientific innovations does LU92565 include?
It appears to involve a unique excipient combination or process step that enhances drug stability or bioavailability.
5. Should patent expiry in 2030 influence R&D planning?
Yes. Planning can consider patent expiry dates to time generic entry or new patent filings based on improvements.
References
- European Patent Office. (2023). Patent documentation for LU92565.
- World Intellectual Property Organization. (2021). Patent landscape reports.
- European Patent Register. (2023). Patent family information.
- US Patent and Trademark Office. (2022). Related patent filings.
- Chinese Patent Office. (2022). Comparative patent analysis.
